The Therapeutic Goods
Administration (TGA) has said it is
monitoring reports of melanoma
in patients being treated with
natalizumab.
The TGA said there had been
three cases of melanoma in
patients being treated with the
drug, marketed as Tysabri in
Australia and used to treat patients
with relapsing-remitting multiple
sclerosis.
An ongoing review of the issue
had not found sufficient evidence
to show a definite link between
natalizumab and the skin cancer.
“However, given the high
incidence of melanoma in Australia,
this remains an issue of concern for
the TGA.”
Health professionals are advised
to monitor patients for any new or
changed skin lesions.The above article was sent to subscribers in Pharmacy Daily's issue from 19 Mar 14 To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 19 Mar 14
THE stark health inequalities between Australians living in regional and metro areas have been highlighted in a new report from The Royal Flying Doctor Service (RFDS).
AN “AI explosion” is sweeping Australia’s healthcare sector, signalling the arrival of an “extraordinary era of medicine”, according to a new report from CSIRO.
THE Australian and New Zealand College of Advanced Pharmacy (ANZCAP) has celebrated the 1,000th pharmacist to complete its pharmacy recognition program (PD 24 Nov 2023).
FREE Pharmacy Daily subscription - never miss another story!
to top
Subscribe to Pharmacy Daily
Pharmacy Daily subscription confirmation
Thank you for signing up! Check your email inbox – you should shortly receive a message with a link which must be clicked to confirm your subscription.
Once you’ve done that you will begin receiving Pharmacy Daily as soon as the next issue is published.